<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03238742</url>
  </required_header>
  <id_info>
    <org_study_id>2017ZDSYLL025-P01</org_study_id>
    <nct_id>NCT03238742</nct_id>
  </id_info>
  <brief_title>The Efficacy of Xuebijing Injection on Sepsis</brief_title>
  <official_title>The Efficacy of Xuebijing Injection in Adult Patients With Sepsis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southeast University, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Health and Family Planning Commission, P.R.China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Southeast University, China</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Efficacy of Xuebijing Injection in Adult Patients with Sepsis&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this placebo-controlled study is to determine if Xuebijing Injection treatment&#xD;
      provides significant mortality reduction improvement in patients with sepsis compared with&#xD;
      placebo treatment in patients receiving the current standard of care for sepsis. This study&#xD;
      will also assess the effectiveness of Xuebijing Injection in reducing 28-day mortality in&#xD;
      patients with sepsis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 20, 2017</start_date>
  <completion_date type="Actual">January 8, 2020</completion_date>
  <primary_completion_date type="Actual">July 28, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel Assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Blind (Participant, Investigator, Outcomes Assessor)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>All-Cause Mortality</measure>
    <time_frame>28 Days after randomization</time_frame>
    <description>Death from all causes at 28-days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Death in ICU</measure>
    <time_frame>28 Days after randomization</time_frame>
    <description>Death from all causes at ICU discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SOFA score</measure>
    <time_frame>Day 0,3,6 after randomization</time_frame>
    <description>Total Sequential Organ Failure Assessment (SOFA) score(0-24) ，higher values represent a worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>APACHEⅡ</measure>
    <time_frame>Day 0,3,6 after randomization</time_frame>
    <description>Acute Physiology and Chronic Health Evaluation (include Acute physiology score, APS and age and Chronic physiology score, totally 0-71 Points)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of mechanical ventilation</measure>
    <time_frame>28 days after randomization</time_frame>
    <description>Duration of mechanical ventilation in ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU stay</measure>
    <time_frame>28 days after randomization</time_frame>
    <description>Duration of stay in ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of C-reactive protein</measure>
    <time_frame>0,3,6days after randomization</time_frame>
    <description>C-reactive protein at 0, 3,6 days after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of Procalcitonin</measure>
    <time_frame>0,3,6 days after randomization</time_frame>
    <description>Procalcitonin at 0,3,6days after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Human Leukocyte Antigen-DR</measure>
    <time_frame>0，6 days after randomization</time_frame>
    <description>Human Leukocyte Antigen-DR at 0, 6 days after randomization</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1817</enrollment>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>Intervention Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100ml Xuebijing Injection will be dissolved in 100 mL of normal saline every 12 hours for 5 days in blind fashion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>normal saline 200 mL every 12 hours for 5 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xuebijing Injection</intervention_name>
    <description>100ml Xuebijing Injection every 12 hours for 5 days</description>
    <arm_group_label>Intervention Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>normal saline</intervention_name>
    <description>200ml normal saline every 12 hours for 5 days</description>
    <arm_group_label>Placebo group</arm_group_label>
    <other_name>NS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients will be eligible for inclusion if all of the inclusion criteria are met&#xD;
&#xD;
          1. Sepsis-3 criteria from Society of Critical Care Medicine (SCCM) /European Society of&#xD;
             Intensive Care Medicine (ESICM)&#xD;
&#xD;
          2. 18≤ age ≤75years&#xD;
&#xD;
          3. 2 ≤SOFA ≤13&#xD;
&#xD;
          4. obtain informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of sepsis for more than 48 h;&#xD;
&#xD;
          2. Pregnant and lactating women;&#xD;
&#xD;
          3. Severe primary disease including unrespectable tumours, blood diseases and Human&#xD;
             Immunodeficiency Virus (HIV);&#xD;
&#xD;
          4. Severe liver and kidney dysfunction (single liver or kidney SOFA score ≥ 3 points);&#xD;
&#xD;
          5. Use of an immunosuppressant or having an organ transplant within the previous 6&#xD;
             months;&#xD;
&#xD;
          6. Participating in other clinical trials in the previous 30 days.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qiu Haibo, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Southeast University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Zhongda Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>July 29, 2017</study_first_submitted>
  <study_first_submitted_qc>August 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2017</study_first_posted>
  <last_update_submitted>January 1, 2021</last_update_submitted>
  <last_update_submitted_qc>January 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Southeast University, China</investigator_affiliation>
    <investigator_full_name>Songqiao Liu</investigator_full_name>
    <investigator_title>Principle investigator</investigator_title>
  </responsible_party>
  <keyword>Xuebijing Injection, morality, sepsis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Mortality</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Study published</ipd_time_frame>
    <ipd_access_criteria>Supplyment</ipd_access_criteria>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>2</doc_id>
      <doc_type>Clinical Review&amp; Education</doc_type>
      <doc_url>http://www.ncbi.nlm.nih.gov/pubmed/26903338</doc_url>
      <doc_comment>Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, Hotchkiss RS, Levy MM, Marshall JC, Martin GS, Opal SM, Rubenfeld GD, van der Poll T, Vincent JL, Angus DC.The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801-10.</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

